Immunome, Inc.
Moat Score — Immunome, Inc.
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Immunome's proprietary HC74 topoisomerase 1 payload and undisclosed linker chemistry, built from screening over 1,000 targets, represent real technical IP, and varegacestat's positive Phase 3 data and pending NDA add a near-term regulatory asset, though much of the portfolio was acquired via licensing/M&A rather than wholly originated in-house. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a clinical-stage biopharma relying entirely on third-party manufacturers, Immunome has no production cost advantage; its economics depend on clinical differentiation and premium oncology pricing rather than cost leadership. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Varegacestat would enter desmoid tumors as a fast-follower to SpringWorks/Merck KGaA's already-approved nirogacestat, meaning Immunome will need to win on differentiated efficacy/safety rather than commanding first-mover pricing power; its other pipeline assets are too early-stage to assess pricing power yet. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Immunome's oncology drug development and eventual sales have no network effect; a given therapy's value to one patient or oncologist does not increase as more patients are treated. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Oncology prescribing decisions are driven by efficacy and safety data at each treatment line rather than by structural switching costs, and as a fast-follower in desmoid tumors Immunome would need to actively displace an incumbent rather than benefit from any switching-cost moat. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Desmoid tumors are a rare-disease market that may support only a small number of profitable competitors, offering Immunome some efficient-scale protection if varegacestat gains share, but its ADC and radioligand programs target larger, more contested oncology markets where efficient-scale protection is far less certain. |